Rein Therapeutics Inc

Rein Therapeutics Inc has a market capitalization of $88.18 million and a price-to-book ratio of 0.97, indicating that the company is trading at a slight discount to its book value. The company has no long-term debt and a current ratio of 2.82, suggesting a strong liquidity position with sufficient current assets to cover its current liabilities. However, the company reported negative operating and free cash flows of $5.27 million and $7.05 million, respectively, indicating ongoing cash burn.

The company's profitability metrics are negative, with a return on equity of -7.79% and a return on assets of -7.17%, both significantly below the industry median for biotechnology firms. The company's net loss of $7.11 million and operating loss of $7.21 million reflect the high costs associated with clinical development and research in the biotechnology sector. The EV/EBITDA ratio is not applicable due to the company's negative EBITDA.

Rein Therapeutics Inc operates in a single business segment focused on gene therapy development, with no geographic revenue concentration disclosed. The company's operations are entirely centered on the development of REN001, with no diversification across products or markets. This lack of diversification increases the company's exposure to clinical trial outcomes and regulatory approval risks.

The company's growth trajectory is speculative, with no revenue reported and a net loss in the most recent period. Analysts have assigned a mean price target of $10.00, implying a potential upside of 760% from the current market price of $1.13. However, the company has not demonstrated revenue growth or profitability, and its future performance is contingent on the success of its clinical trials and regulatory approvals.

The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and lack of revenue raise concerns about its ability to fund operations without additional financing. The company has not issued shares in the recent past, and there is no indication of dilution pressure in the near term. The absence of long-term debt reduces financial leverage risk, but the company's reliance on equity financing could lead to future dilution.

Recent events include the initiation of a Phase 1/2 clinical trial for REN001 in the second quarter of 2024. The company has not disclosed any recent earnings calls or investor presentations, and there are no recent 10-K or 10-Q filings available for analysis. The company's progress in clinical development is a key driver of its valuation and future prospects.

Rein Therapeutics Inc (RNTX.O) has recorded a notable addition to its shareholder base, marking the first analysis for this ticker with no prior basis for delta computation. The most material change identified is a new holder entry detected on June 20, 2026, which signals fresh institutional or significant investor interest in the company's equity. As of June 30, 2024, the new investor, identified by ID 466, acquired 31,285 shares valued at approximately $0.087 million. This position represents a weight of roughly 0.0002% of the total holdings, indicating a relatively small but distinct entry into the company's capital structure. This development is significant given Rein Therapeutics' current corporate profile, which includes a single officer and no analyst coverage. The absence of analyst estimates and index membership suggests the stock is largely overlooked by mainstream financial research, making any new holder activity a key indicator of potential interest in the absence of broader market consensus. With seven top holders currently on record, the addition of this new stakeholder contributes to the evolving ownership landscape of the biotech firm. While the financial and ESG fundamentals remain documented in available reports, this specific holder change provides the first concrete signal of shifting investor sentiment for the ticker.

Analysts project 774% upside to a consensus price target of $8.00, signaling strong institutional confidence in future value.

Return on equity of -7.79% outperforms the biotechnology cohort median of -21.82%, indicating relatively efficient capital preservation.

The company maintains zero long-term debt across all reported fiscal years, eliminating interest expense and refinancing risks entirely.

Operating losses improved by 22.2% year-over-year in FY2026, suggesting a potential stabilization trend in cost management efforts.

Low dilution, liquidity, and credit risk flags indicate a stable financial profile despite the absence of commercial revenue generation.

The company generated zero revenue across all five reported fiscal years, highlighting a complete lack of commercial product sales.

Net losses widened significantly to $62.9 million in FY2025 before narrowing, demonstrating persistent and volatile profitability challenges.

Negative free cash flow of $49.9 million in FY2026 confirms ongoing cash burn requiring continuous external capital funding.

A current ratio of 0.7 indicates potential short-term liquidity constraints, as current liabilities exceed current assets significantly.

Cash conversion efficiency of 0.74 trails the biotechnology cohort median of 0.87, reflecting inferior operational cash generation.

Revenue $0.00; Operating income +23,7% YoY.

• ▍Revenue $0.00
• ▍Operating income +23,7% YoY
• ▍Net income +22,0% YoY
• ▍Free cash flow +22,0% YoY

Revenue $0.00; Operating income +9,5% YoY.

• ▍Revenue $0.00
• ▍Operating income +9,5% YoY
• ▍Net income +4,5% YoY
• ▍Free cash flow +4,5% YoY

Revenue $0.00; Operating income +24,0% YoY.

• ▍Revenue $0.00
• ▍Operating income +24,0% YoY
• ▍Net income +23,7% YoY
• ▍Free cash flow +23,7% YoY

Revenue $0.00; Operating income +22,1% YoY.

• ▍Revenue $0.00
• ▍Operating income +22,1% YoY
• ▍Net income +22,7% YoY
• ▍Free cash flow +22,0% YoY

Revenue $0.00; Operating income -$42.8M.

• ▍Revenue $0.00
• ▍Operating income -$42.8M

Revenue $0.00; Operating income -$6.1M.

• ▍Revenue $0.00
• ▍Operating income -$6.1M

Revenue $0.00; Operating income -$9.0M.

• ▍Revenue $0.00
• ▍Operating income -$9.0M

Revenue $0.00; Operating income -$7.2M.

• ▍Revenue $0.00
• ▍Operating income -$7.2M

Revenue $0.00; Operating income +22,2% YoY.

• ▍Revenue $0.00
• ▍Operating income +22,2% YoY
• ▍Net income +20,7% YoY
• ▍Free cash flow +20,6% YoY

Revenue $0.00; Operating income −300,1% YoY.

• ▍Revenue $0.00
• ▍Operating income −300,1% YoY
• ▍Net income −299,7% YoY
• ▍Free cash flow −302,4% YoY

Revenue $0.00; Operating income +41,1% YoY.

• ▍Revenue $0.00
• ▍Operating income +41,1% YoY
• ▍Net income +42,4% YoY
• ▍Free cash flow +42,5% YoY

Revenue $0.00; Operating income −5,1% YoY.

• ▍Revenue $0.00
• ▍Operating income −5,1% YoY
• ▍Net income −4,5% YoY
• ▍Free cash flow −3,7% YoY